• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

CHADS-VASc评分与GRACE评分在评估心房颤动合并急性冠状动脉综合征或经皮冠状动脉介入治疗患者长期缺血事件风险中的临床应用

Clinical Application of CHADS-VASc versus GRACE Scores for Assessing the Risk of Long-term Ischemic Events in Atrial Fibrillation and Acute Coronary Syndrome or PCI.

作者信息

Mo Ran, Yang Yan-Min, Zhang Han, Suo Ni, Wang Jing-Yang, Lyu Si-Qi

机构信息

Emergency Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 100037 Beijing, China.

National Clinical Research Center of Cardiovascular Diseases, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 100037 Beijing, China.

出版信息

Rev Cardiovasc Med. 2022 May 11;23(5):168. doi: 10.31083/j.rcm2305168. eCollection 2022 May.

DOI:10.31083/j.rcm2305168
PMID:39077589
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11273896/
Abstract

BACKGROUND

Early risk stratification of patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI) has relevant implication for individualized management strategies. The -VASc and GRACE ACS risk model are well-established risk stratification systems. We aimed to assess their prognostic performance in AF patients with ACS or PCI.

METHODS

Consecutive patients with AF and ACS or referred for PCI were prospectively recruited and followed up for 3 years. The primary endpoint was major adverse cardiovascular and cerebrovascular events (MACCEs), including cardiovascular mortality, myocardial infarction, ischemic stroke, systemic embolism and ischemia-driven revascularization.

RESULTS

Higher -VASc (HR [hazard ratio] 1.184, 95% CI 1.091-1.284) and GRACE at discharge score (HR 1.009, 95% CI 1.004-1.014) were independently associated with increased risk of MACCEs. The -VASc (c-statistics: 0.677) and GRACE at discharge (c-statistics: 0.699) demonstrated comparable discriminative capacity for MACCEs ( = 0.281) while GRACE at admission provided relatively lower discrimination (c-statistics: 0.629, vs. -VASc = 0.041). For predicting all-cause mortality, three models displayed good discriminative capacity (c-statistics: 0.750 for -VASc, 0.775 for GRACE at admission, 0.846 for GRACE at discharge). A significant discrimination improvement of GRACE at discharge compared to -VASc was detected (NRI = 45.13%).

CONCLUSIONS

In the setting of coexistence of AF and ACS or PCI, -VASc and GRACE at discharge score were independently associated with an increased risk of MACCEs. The GRACE at discharge performed better in predicting all-cause mortality.

摘要

背景

心房颤动(AF)合并急性冠状动脉综合征(ACS)或接受经皮冠状动脉介入治疗(PCI)患者的早期风险分层对个体化管理策略具有重要意义。-VASc和GRACE ACS风险模型是成熟的风险分层系统。我们旨在评估它们在AF合并ACS或PCI患者中的预后性能。

方法

前瞻性招募连续的AF合并ACS患者或接受PCI治疗的患者,并随访3年。主要终点是主要不良心血管和脑血管事件(MACCEs),包括心血管死亡、心肌梗死、缺血性中风、全身性栓塞和缺血驱动的血运重建。

结果

较高的-VASc(风险比[HR]1.184,95%可信区间1.091-1.284)和出院时的GRACE评分(HR 1.009,95%可信区间1.004-1.014)与MACCEs风险增加独立相关。-VASc(c统计量:0.677)和出院时的GRACE(c统计量:0.699)对MACCEs的判别能力相当(=0.281),而入院时的GRACE判别能力相对较低(c统计量:0.629,与-VASc相比P=0.041)。对于预测全因死亡率,三种模型均显示出良好的判别能力(-VASc的c统计量:0.750,入院时GRACE的c统计量:0.775,出院时GRACE的c统计量:0.846)。与-VASc相比,出院时GRACE的判别能力有显著提高(净重新分类指数[NRI]=45.13%)。

结论

在AF与ACS或PCI并存的情况下,-VASc和出院时的GRACE评分与MACCEs风险增加独立相关。出院时的GRACE在预测全因死亡率方面表现更好。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e69/11273896/a98400a99845/2153-8174-23-5-168-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e69/11273896/9432d8364b56/2153-8174-23-5-168-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e69/11273896/3e59024182c8/2153-8174-23-5-168-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e69/11273896/a98400a99845/2153-8174-23-5-168-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e69/11273896/9432d8364b56/2153-8174-23-5-168-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e69/11273896/3e59024182c8/2153-8174-23-5-168-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e69/11273896/a98400a99845/2153-8174-23-5-168-g3.jpg

相似文献

1
Clinical Application of CHADS-VASc versus GRACE Scores for Assessing the Risk of Long-term Ischemic Events in Atrial Fibrillation and Acute Coronary Syndrome or PCI.CHADS-VASc评分与GRACE评分在评估心房颤动合并急性冠状动脉综合征或经皮冠状动脉介入治疗患者长期缺血事件风险中的临床应用
Rev Cardiovasc Med. 2022 May 11;23(5):168. doi: 10.31083/j.rcm2305168. eCollection 2022 May.
2
Prognostic value of GRACE and CHA2DS2-VASc score among patients with atrial fibrillation undergoing percutaneous coronary intervention.GRACE和CHA2DS2-VASc评分在接受经皮冠状动脉介入治疗的房颤患者中的预后价值。
Ann Med. 2021 Dec;53(1):2215-2224. doi: 10.1080/07853890.2021.2004321.
3
Prognostic value of CHADS2 and CHA2DS2-VASc scores for post-discharge outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention.CHADS2和CHA2DS2-VASc评分对接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者出院后结局的预后价值。
Medicine (Baltimore). 2020 Jul 24;99(30):e21321. doi: 10.1097/MD.0000000000021321.
4
Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy.在接受经皮冠状动脉介入治疗并接受双联抗血小板治疗出院的无房颤患者中,CHA2DS2-VASc和HAS-BLED评分的预测准确性。
Int J Cardiol. 2015 Nov 15;199:319-25. doi: 10.1016/j.ijcard.2015.07.064. Epub 2015 Jul 26.
5
Usefulness of the CHADS-VASc Score to Predict Adverse Outcomes in Acute Coronary Syndrome Patients Without Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.CHADS-VASc 评分在经皮冠状动脉介入治疗的无房颤急性冠状动脉综合征患者中预测不良结局的价值。
Am J Cardiol. 2019 Aug 15;124(4):476-484. doi: 10.1016/j.amjcard.2019.05.036. Epub 2019 May 29.
6
Mid-term Risk Stratification of Patients with a Myocardial Infarction and Atrial Fibrillation: Beyond GRACE and CHADS.心肌梗死合并心房颤动患者的中期风险分层:超越GRACE和CHADS
J Atr Fibrillation. 2013 Dec 31;6(4):897. doi: 10.4022/jafib.897. eCollection 2013 Dec.
7
CHADS2, CHA2DS2-VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention.CHADS2、CHA2DS2-VASc和HAS-BLED作为接受经皮冠状动脉介入治疗的房颤患者预后的预测指标。
Thromb Res. 2014 Apr;133(4):560-6. doi: 10.1016/j.thromres.2014.01.007. Epub 2014 Jan 11.
8
The Predictive Value of CHADS-VASc Score on In-Hospital Death and Adverse Periprocedural Events Among Patients With the Acute Coronary Syndrome and Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention: A 10-Year National Inpatient Sample (NIS) Analysis.CHADS-VASc评分对接受经皮冠状动脉介入治疗的急性冠状动脉综合征合并心房颤动患者住院死亡及围手术期不良事件的预测价值:一项为期10年的全国住院患者样本(NIS)分析
Cardiovasc Revasc Med. 2021 Aug;29:61-68. doi: 10.1016/j.carrev.2020.08.003. Epub 2020 Aug 7.
9
Impact of Ticagrelor vs. Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention After Risk Stratification With the CHADS-VASc Score.在采用CHADS-VASc评分进行风险分层后,替格瑞洛与氯吡格雷对接受经皮冠状动脉介入治疗的急性冠状动脉综合征患者的影响。
Front Cardiovasc Med. 2022 Apr 4;9:808571. doi: 10.3389/fcvm.2022.808571. eCollection 2022.
10
The prognostic value of CHADS-VASc and GRACE risk scores in patients with ACS.ACS 患者中 CHADS-VASc 和 GRACE 风险评分的预后价值。
Hellenic J Cardiol. 2019 Sep-Oct;60(5):305-308. doi: 10.1016/j.hjc.2018.03.001. Epub 2018 Mar 27.

引用本文的文献

1
Rate control or rhythm control in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention.心房颤动合并急性冠状动脉综合征或经皮冠状动脉介入治疗患者的心率控制或节律控制。
Heliyon. 2024 Jul 25;10(15):e35218. doi: 10.1016/j.heliyon.2024.e35218. eCollection 2024 Aug 15.
2
Heart Failure and Major Adverse Cardiovascular Events in Atrial Fibrillation Patients: A Retrospective Primary Care Cohort Study.心房颤动患者的心力衰竭与主要不良心血管事件:一项回顾性初级保健队列研究
Biomedicines. 2023 Jun 26;11(7):1825. doi: 10.3390/biomedicines11071825.

本文引用的文献

1
Prognostic value of GRACE and CHA2DS2-VASc score among patients with atrial fibrillation undergoing percutaneous coronary intervention.GRACE和CHA2DS2-VASc评分在接受经皮冠状动脉介入治疗的房颤患者中的预后价值。
Ann Med. 2021 Dec;53(1):2215-2224. doi: 10.1080/07853890.2021.2004321.
2
Second-generation laser balloon ablation for the treatment of atrial fibrillation assessed by continuous rhythm monitoring: the LIGHT-AF study.第二代激光球囊消融术通过连续节律监测评估治疗心房颤动:LIGHT-AF 研究。
Europace. 2021 Sep 8;23(9):1380-1390. doi: 10.1093/europace/euab085.
3
Targeting Bachmann's bundle in hybrid ablation for long-standing persistent atrial fibrillation: a proof of concept study.
针对长程持续性心房颤动的杂交消融中 Bachmann's 束的靶向治疗:一项概念验证研究。
J Interv Card Electrophysiol. 2022 Aug;64(2):273-280. doi: 10.1007/s10840-021-00971-7. Epub 2021 Mar 8.
4
Impact of Atrial Fibrillation on Acute Coronary Syndrome-Analysis of In-Hospital Outcomes and 30-Day Readmissions.心房颤动对急性冠状动脉综合征的影响-院内结局和 30 天再入院分析。
Curr Probl Cardiol. 2021 Apr;46(4):100764. doi: 10.1016/j.cpcardiol.2020.100764. Epub 2020 Dec 13.
5
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.2020年欧洲心脏病学会(ESC)与欧洲心胸外科学会(EACTS)合作制定的心房颤动诊断和管理指南:欧洲心脏病学会(ESC)心房颤动诊断和管理特别工作组,由ESC欧洲心律协会(EHRA)特别贡献制定。
Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.
6
CHADS-VASc score as predictor of stroke and all-cause death in stable ischaemic heart disease patients without atrial fibrillation.CHADS-VASc 评分预测稳定性缺血性心脏病患者无房颤时的卒中和全因死亡。
J Neurol. 2020 Oct;267(10):3061-3068. doi: 10.1007/s00415-020-09961-7. Epub 2020 Jun 11.
7
A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial.对利伐沙班在心力衰竭、冠心病和窦性心律患者中对卒中或短暂性脑缺血发作影响的综合分析:COMMANDER HF 试验。
Eur Heart J. 2019 Nov 21;40(44):3593-3602. doi: 10.1093/eurheartj/ehz427.
8
Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF.新发心房颤动与急性冠状动脉综合征病史的结局:来自 GARFIELD-AF 的见解。
Am J Med. 2019 Dec;132(12):1431-1440.e7. doi: 10.1016/j.amjmed.2019.06.008. Epub 2019 Jul 12.
9
Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association.《2019年心脏病和中风统计数据更新:美国心脏协会报告》
Circulation. 2019 Mar 5;139(10):e56-e528. doi: 10.1161/CIR.0000000000000659.
10
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons.2019年美国心脏协会/美国心脏病学会/心律学会对2014年美国心脏协会/美国心脏病学会/心律学会心房颤动患者管理指南的聚焦更新:美国心脏病学会/美国心脏协会临床实践指南工作组和心律学会与胸外科医师协会合作报告
Circulation. 2019 Jul 9;140(2):e125-e151. doi: 10.1161/CIR.0000000000000665. Epub 2019 Jan 28.